Abstract
Pancreatic cancer (PC) is known for its high malignancy and poor prognosis.Furthermore,PC patients have little chance to receive an operation,and chemotherapy is not always an ideal alternative.More effective treatment is necessary because over the last two decades,the morbidity and the mortality of PC has risen continuously.Some new PC treatments involve HER2,a transmembrane protein that has oncological significance.The amplification of its gene or over expression of itself can cause malignant proliferation,suppression of apoptosis,and angiogenesis in PC.Its potential can be seen with HER2 targeted medicines including the clinically used Trastuzumab,but also with bispecific antibody,tyrosine kinase inhibitors,and more.This article will review the application of these new developments. Key words: Pancreatic neoplasms; Receptor, epidermal growth factor; Antibodies, monoclonal; Tyrosine Kinase Inhibitors; Biological therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
